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Background: Although the negative impact of sleep apnea on the clinical course of acute ischemic stroke (AIS) is
well known, data regarding non-invasive ventilation in acute patients are scarce. Several studies have shown its
tolerability and safety, yet no controlled randomized sequential phase studies exist that aim to establish the efficacy
of early non-invasive ventilation in AIS patients.
Methods/design: We decided to examine our hypothesis that early non-invasive ventilation with auto-titrating
bilevel positive airway pressure (auto-BPAP) positively affects short-term clinical outcomes in AIS patients. We
perform a multicenter, prospective, randomized, controlled, third rater- blinded, parallel-group trial. Patients with AIS
with proximal arterial obstruction and clinically suspected sleep apnea will be randomized to standard stroke care
alone or standard stroke care plus auto-BPAP. Auto-BPAP will be initiated within 24 hours of stroke onset and
performed for a maximum of 48 hours during diurnal and nocturnal sleep. Patients will undergo unattended
cardiorespiratory polygraphy between days three and five to assess sleep apnea. Our primary endpoint will be
any early neurological improvement on the NIHSS at 72 hours from randomization. Safety, tolerability, short-term
and three-months functional outcomes will be assessed as secondary endpoints by un-blinded and blinded
observers respectively.
Discussion: We expect that this study will advance our understanding of how early treatment with non-invasive
ventilation can counterbalance, or possibly reverse, the deleterious effects of sleep apnea in the acute phase of
ischemic stroke. The study will provide preliminary data to power a subsequent phase III study.
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Stroke still constitutes a leading cause of death and ranks
number one among all causes of serious long-term adult
disability in Europe and the United States [1,2], under-
scoring the need for adjuvant acute and preventive stroke
therapies that reduce both the devastating human and
economic burden of this disease.
More than two-thirds of acute ischemic stroke (AIS) pa-
tients suffer from sleep apnea of variable degree compared
to 5 to 15% in the general population [3-6]. Moreover, in a
prospective cohort study, patients with moderate to severe
obstructive sleep apnea (OSA) had an almost two-fold
increased risk for stroke and death after adjustment for
other traditional vascular risk factors, thus establishing
OSA as an independent risk factor [7,8]. Following stroke,
sleep apnea negatively affects the length of hospitalization
and short-term as well as long-term outcomes, likely
through its association with an increased risk of neuro-
logical deterioration during acute and subacute phases
of stroke [4,9-12]. Neurological deterioration during the
early phase of AIS can occur between one and two out
of five patients and it is independently predicted by sleep
apnea and associated with unfavorable outcome [9,13].
Numerous studies including serial transcranial Doppler
(TCD) in patients with AIS provided evidence that
persisting large-artery steno-occlusive disease and cor-
responding collateral failure, leading to depletion of oxy-
gen and nutrients to penumbral tissues, appear to be the
most relevant pathogenic mechanisms for neurological
deterioration [14-17]. Thus, it seems intuitive that fur-
ther hemodynamic and perfusion derangements may
do harm by facilitating hypoperfusion and ultimately
lead to expansion of infarction to penumbral areas (or
even oligemic tissues surrounding the ischemic pen-
umbra) with neurological deterioration as the clinical
correlate [18].
Several pathophysiological conditions associated with
sleep apnea are believed to account for acute harmful ef-
fects on ischemic brain [19]. Recurrent nocturnal apneic
episodes promptly entail intermittent hypoxemia, intra-
thoracic pressure changes and activation of the sympa-
thetic nervous system resulting in cardiac arrhythmias
and marked blood pressure swings [20,21]. The cerebral
autoregulatory system is essential to compensate for changes
in systemic hemodynamics and to avoid harmful hypo- or
hyperperfusion of brain tissue. The fate of ischemic brain
tissues particularly in the setting of large steno-occlusive
disease already depend on dilated arteries with no further
or only minimal residual vasomotor capacity [22-24] to
counteract apnea-associated blood pressure changes and
maintain blood flow according to local metabolic needs
[19]. In fact, patients with sleep apnea generally have
impaired cerebral vasoreactivity, even during wakeful-
ness, potentially explaining their particular vulnerabilityto stroke-associated hemodynamic derangements [25-28].
Repetitive oxygen desaturations in cerebral ischemic tissue
during apneic periods may further compromise functional
and structural integrity of neuronal cells [29]. Addition-
ally, hypercapnia may lead to depletion of the collateral
blood flow when vessels in the non-ischemic area dilate
more leading to blood flow diversion from the ischemic
area to the non-ischemic areas, possibly further worsening
hypoperfusion in the ischemic brain area [23,30,31]. This
‘cerebral blood flow steal’ phenomenon was demonstrated
by TCD in real time in AIS patients during voluntary
breath holding and led to early neurological deterioration
in those with acute proximal arterial obstructions and
excessive daytime sleepiness [10]. When found during
the initial hospitalization for AIS, this so called ‘re-
versed Robin Hood syndrome’ led to a four-fold in-
crease in stroke recurrence within the same arterial
territory [11].
Maintenance of stable systemic and cerebral hemody-
namics, as well as adequate and constant brain tissue oxy-
genation, plays a crucial role in the management of AIS
[32]. The ischemic penumbra may be present for many
hours and be amenable to reperfusion. Consequently, any
treatment that potentially maintains or augments cerebral
perfusion may be justified [33]. Non-invasive ventilation
with either continuous (CPAP) or bilevel positive airway
pressure (BPAP) is the treatment of choice for sleep apnea.
Although some studies have shown the safety and beneficial
effects of CPAP and BPAP by improvement of quality of life
and reduction of cardio- and cerebrovascular morbidity and
mortality in the general sleep apnea population [34,35],
their role in AIS patients remains to be elucidated. Most
previous investigations were conducted beyond the (hyper-)
acute phase of ischemic stroke and pursued secondary
stroke prevention goals rather than acute effects. For ex-
ample, two studies confirmed safety and tolerability, and
pointed to a potential short-term treatment effect of
prompt initiation of non-invasive ventilation in the acute
phase of stroke when hemodynamically compromised
tissue can potentially be salvaged [36,37]. In the first
study, an observational study, AIS patients with proximal
persisting arterial occlusions and suspected or known
OSA had a tendency towards early neurological improve-
ment (median National Institutes of Health Stroke Scale
(NIHSS) score decrease by 2 points) during the hospital
course when BPAP was initiated within the first 24 hours
of admission, as compared with those who did not re-
ceive BPAP (median NIHSS score decrease by 1 point,
P = 0.078) [36]. The other study randomly assigned
fifty patients in the first night after AIS to either
CPAP for three nights or control [37]. The investiga-
tors found that CPAP treatment was feasible, safe and
associated with a greater neurological improvement
until day eight in patients who tolerated CPAP well
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1.4, P = 0.022).
As data on the use of non-invasive ventilation in
the acute phase of ischemic stroke are lacking and its
potential benefit on stroke outcomes is controversial
[38], a randomized controlled efficacy trial appears justi-
fied as being timely and needed. The choice of using an
auto-titrating BPAP ventilation mode is based on the
fact that AIS patients will not have the necessary time
or access to facilities to undergo comprehensive sleep
laboratory testing prior to start of treatment. Auto-
BPAP adapts pressure settings automatically according
to apnea frequency recorded in real-time from breath-
to-breath, thus sparing manual titration of therapeutic
pressures. Also, BPAP mode delivers pressure levels
for inspiration and expiration separately, easing inspir-
ation while ensuring alveolar ventilation and splinting
the airway, which has several advantages over standard
CPAP that applies a fixed pressure setting during the
entire respiratory cycle [39]. Collectively, auto-BPAP
may be superior particularly in patients who require
higher pressure levels [39,40] and produces improved
patient adherence, a well-known issue in recent studies
that may be even more important for stroke patients
who may not have appropriate understanding and mo-
tivation to allow themselves to be exposed to mask and
airflow pressures. Finally, this approach could be uti-
lized in stroke centers without experience in sleep
medicine.Methods
Study design
This is an international, multicenter, prospective, ran-
domized, controlled, third rater-blinded, parallel-group
phase II study (Clinicaltrials.gov identifier: NCT01812993).
A double-blind study design would require sham venti-
latory treatment that is impossible in this setting. A
sham mask device with subtherapeutic pressures may
also pose a risk of harm as it will likely preclude ad-
equate ventilation and increase the respiratory ‘dead
space’ volume. Thus, to minimize bias associated with
an open-label study, a trained neurologist or nurse
blinded to treatment allocation will assess the primary
and, whenever applicable, secondary efficacy outcomes.
The study protocol has received full ethics approval by
the Institutional Review Board of the University of
Technology Dresden (Reference number: EK 362112012).Patient population
Using a convenience sampling method, patients present-
ing to one of the participating stroke centers with AIS due
to intra- or extracranial arterial steno-occlusive obstruc-
tion and clinically suspected sleep apnea will be eligiblefor the study. Patients will have to meet the following
inclusion and exclusion criteria:
Inclusion criteria
 Male and female patients 18 to 80 years;
 Clinical suspicion of an AIS (measurable or
fluctuating neurological deficit with a NIHSS ≥ 4
points) within 24 hours from symptom onset;
 Extracranial (that is, internal carotid artery) or
intracranial (that is, internal carotid artery; middle/
anterior/posterior cerebral arteries) ≥ 50% stenosis,
near-occlusion or occlusion diagnosed by
ultrasound, computed tomography angiography
(CTA) or magnetic resonance angiography (MRA),
corresponding to the acute neurological deficit;
 High risk of having sleep apnea (classified by the
Berlin sleep apnea questionnaire); or history of
known sleep apnea; or witnessed repetitive apneic
episodes during sleep or somnolence during
hospitalization;
 Written informed consent by participants;
alternatively by proxy or two physicians when not
obtainable by patient or proxy (according to local
regulations).
Exclusion criteria
 Perceived course towards malignant middle cerebral
artery infarction;
 Vertebrobasilar ischemic stroke;
 Immediate or perceived need for intubation;
 Known sleep apnea currently on non-invasive
ventilatory treatment;
 Standard contraindications for non-invasive
ventilatory treatment;
 Pre-morbid modified Rankin scale (mRS) score ≥ 3;
 Severe comorbidities (that is, severe heart failure,
severe obstructive lung disease, active malignant
disease, severe dementia);
 Pregnant and breast-feeding women;
 Participation in another clinical trial other than
standard-of-care registry.
Randomization
All randomization procedures are prepared and moni-
tored by the Dresden Coordination Center for Clinical
Studies, independent of patient recruitment and imple-
mentation of the assignment. After eligibility for the study
has been confirmed, written informed consent obtained
and baseline assessments completed, a 1:1 randomized
allocation to either standard stroke care alone (no venti-
latory treatment = control) or standard stroke care plus
non-invasive ventilatory treatment with auto-BPAP will
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dom number (nQuery Advisor® PPS 6.01, Saugus, MA,
USA) that is provided via the online Research Electronic
Data Capture (REDCap) system [41]. The allocation se-
quences are concealed from investigators involved in
patient recruitment and collection of outcome data.
Stratified block randomization with strata for study site
and stroke severity as defined by the NIHSS (that is, 4
to 10 and > 10 points) will be used, wherein the block
size is fixed and will not be communicated to any of the
investigators with clinical involvement in this trial.
Study procedures
Study physicians will obtain baseline NIHSS scores,
determine patient eligibility and obtain informed written
consent from each patient prior to any study-related proce-
dures. Patients allocated to the active group will receive
non-invasive ventilatory treatment with auto-BPAP (Philips
Respironics, Auto-BIPAP Biflex®, Herrsching, Germany)
within 24 hours of symptom onset, and for a maximum
of 48 hours during diurnal and nocturnal sleep or som-
nolence, from the beginning of study randomization
(Figure 1). This approach warrants that all patients in the
active group will receive an intention-to-treat all potential
apneic episodes independently of their sleep cycle and
somnolence. During the study period, oral and tube feed-
ing intake will be allowed according to local institutional
protocols. The auto-BPAP device automatically adjusts ex-
piratory (EPAP) and inspiratory positive airway pressure
(IPAP) levels to meet patients’ needs and will be config-
ured to pressure settings that are identical in all patientsFigure 1 Study flowchart. NIHSS indicates National Institutes of Health St
Rankin Scale.in the active group: possible minimum EPAP 4 mbar;
possible maximum IPAP 25 mbar; maximum difference
between EPAP and IPAP (delta) 8 mbar; Biflex 2. The
device records sleep-related respiratory events as well as
duration of its use. Attachment of the device and initi-
ation of treatment is performed by the study personnel
who will receive training specific to the device by a sleep
neurologist experienced with the study device.
All patients will undergo a diagnostic unattended car-
diorespiratory polygraphy between days three and five
from enrollment for assessment of sleep apnea using a
previously established protocol [5]. A rater experienced
in sleep medicine and who is unaware of group alloca-
tion and clinical data will analyze the sleep polygram.Primary aim
The primary aim is to determine if early auto-BPAP ini-
tiated within the acute phase of ischemic stroke affects
short-term clinical outcome. The signal-of-efficacy in these
patients will be determined if these early changes in the
neurological deficit could be sustained at three months
from symptom onset.Primary endpoint
Early neurological recovery will be assessed as any im-
provement on the NIHSS score at 72 ± 12 hours from
randomization. Physicians or qualified study personnel,
other than those involved in acute treatment (that is,
blinded to randomization) and who are certified in
performing NIHSS scoring, will obtain the NIHSS scores.roke Scale Score. BPAP, bilevel positive airway pressure. mRS, modified
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Secondary aims are comprised of the assessment of
tolerability and safety of auto-BPAP initiated within the
acute phase of ischemic stroke, as well as its possible effect
on other clinical outcomes during hospitalization and
follow-up (signal-of-efficacy).
Secondary endpoints
Tolerability will be assessed by patient adherence to
auto-BPAP (defined as tolerating the treatment during
sleep or somnolence for at least four hours continuously).
Safety will be assessed by:
(i) frequency of serious adverse events (that is,
aspiration, aspiration pneumonia defined as
combined radiologic, white blood count and clinical
findings, respiratory failure with/without intubation)
during treatment period that in the opinion of the
study physician are causatively and timely (for a
maximum of 72 hours from treatment initiation)
related to auto-BPAP. For comparison, patients in
the control group will be monitored for respiratory
complications within 72 hours from randomization.
All deaths in both groups during hospital stay;
(ii) frequency of all complaints and possible side effects
of auto-BPAP (that is, local irritation of skin/mucosa,
mucosal dryness, nausea/vomiting);
(iii) any concerns by hospital nursing staff will be
documented as adverse events since patients will be
under standard of care repeated assessments set by
admission protocols and treating physicians.
Signal-of-efficacy:
Clinical and functional outcomes will be assessed by:
(i) frequency of neurological deterioration (increase in
baseline NIHSS score ≥ 4 points) at 24, 48 and after
72 hours from randomization by blinded observers;
(ii) frequency of early neurological improvement
(decrease in baseline NIHSS score ≥ 4 points) at 24,
48 and after 72 hours from randomization by
blinded observers;
(iii) good functional outcome (mRS score 0 to 2) at
discharge and at three months by blinded observers,
and ordinal analysis of the mRS at three months;
(iv) all deaths and any TIA or new ischemic stroke
during hospitalization or within three months of
protocol initiation.
Data Safety Monitoring Board (DSMB)
Serious adverse events (SAE) as described above and un-
expected SAE will be collected for the first 72 hoursfrom initiation of auto-BPAP. All SAEs will be reported
by fax or Email within 24 hours from occurrence to the
DSMB that is composed of two clinicians and a biostat-
istician at the University of Technology Dresden who is
not involved in the execution of this study. In the event
of an SAE, subjects in the auto-BPAP arm will immedi-
ately have the procedure terminated, and will receive
stabilizing procedures. All SAEs must be reported within
24 hours, and will require submission of incident find-
ings and associated events by the local principal investi-
gator to the DSMB for adjudication. From our pilot
study [36], we expect SAEs to occur in less than one in
ten enrolled patients. If there is one SAE in the first 10
patients, the study will continue. If there are two SAEs
in the first 10 patients then the study will stopped and
DSMB will make recommendations if certain criteria/
exposures need to be modified. The study will be halted
if treatment with auto-BPAP results in more than two
SAEs per 10 patients. Thereafter, DSMB will receive
monthly enrollment/safety/outcomes reports. Addition-
ally, DSMB will be convened any time that safety or data
concerns arise. DSMB will also have access to unblinded
data, to make decisions if higher than expected rates of
SAEs are being outweighed by potential benefits; no fur-
ther criteria for stopping the trial will be set as limited
data are available to guide such algorithms at this point.Sample size
Sample size estimates were calculated from a previous
randomized feasibility study [37], where a significantly
greater improvement in the NIHSS score was observed
when AIS patients were treated with CPAP as compared
with controls (mean 2.3 versus 1.4 points, P = 0.022).
This minimal difference of 0.9 points in NIHSS improve-
ment between the groups was considered clinically rele-
vant. Assuming a two-sided 5% significance level and 80%
power, 24 patients in each group (48 patients in total)
would be needed to detect such a difference in the mean
NIHSS score at 72 hours (nQuery Advisor ® 6.01, Saugus,
MA, USA). In order to reflect missing data and possible
issues with tolerability (for example, loss to follow-up,
lack of patient compliance) at a maximum rate of 20%,
the sample size for this study is set at 60 patients (30
per group).
To minimize missing data in this trial, all outcome
assessments will be electronically scheduled for each
enrolled patient and reminders will be electronically
generated and delivered to the assessors on time. Also,
to prevent drop-outs due to non-compliance with auto-
BPAP in the active treatment arm, patients will be closely
monitored by a carefully trained nurse to enhance toler-
ability of the auto-BPAP device. After discharge, all pa-
tients will be contacted and interviewed either face-to-face
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cate, proxies will be involved.
Planned statistical analysis
Research Electronic Data Capture (REDCap) [41] will be
used for recruitment and data management in this study.
The primary analysis will be an intention-to-treat ana-
lysis in which all subjects are retained in the group to
which they were allocated and included in the analysis,
irrespective of their compliance with allocated treatment.
Statistical analysis in this population is used to deter-
mine statistical significance. The per-protocol population
with inclusion of all patients without major protocol viola-
tions will be also analyzed. For confirmatory analysis, the
primary endpoint will be assessed using the Mann-Whitney
U-test. For secondary endpoints, categorical variables will
be assessed using Chi-square tests or Fisher’s exact test,
while continuous variables will be assessed using Student’s
t-test and the Wilcoxon rank sum test, where appropriate.
With regard to the exploratory analysis, adjustments
will not be made for multiple comparisons. Multivariate
analysis will be performed to define positive and nega-
tive predictors of specific primary and secondary out-
comes. Last-observation-carried-forward method will be
used to impute missing data. Statistical significance will
be declared if the two-tailed P-value will be less than
0.05. Two-sided 95% confidence intervals will be calcu-
lated for continuous variables. All statistical analyses will
be performed with SPSS (SPSS Inc., Chicago, IL, USA)
and SAS (SAS Institute, Inc., Cary, NC, USA) software.
Discussion
We expect that this study will advance our understand-
ing of how early treatment with non-invasive ventilatory
treatment can counterbalance, or possibly reverse, the
deleterious effects of sleep apnea in the acute phase of
ischemic stroke. Our assumptions for sample size were
based on a relatively small effect size as even slight im-
provements on the NIHSS score appear to be a strong
predictor of good functional outcome after stroke [42].
The study will provide preliminary data to power a
phase III study of auto-BPAP in the acute phase of cere-
bral ischemia.
Trial status
At the time of manuscript submission, recruitment of
study patients is ongoing. Initial recruitment was started
in May 2013.
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